Roivant Sciences (NASDAQ:ROIV – Get Free Report) is expected to release its Q2 2027 results before the market opens on Monday, November 9th. Analysts expect Roivant Sciences to post earnings of ($0.3666) per share and revenue of $4.14 million for the quarter. Investors can check the company’s upcoming Q2 2027 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 8:00 AM ET.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. On average, analysts expect Roivant Sciences to post ($2.00) EPS for the current fiscal year and ($2.23) EPS for the next fiscal year.
Roivant Sciences Stock Performance
NASDAQ ROIV opened at $36.91 on Monday. The company has a market capitalization of $26.66 billion, a price-to-earnings ratio of -69.64 and a beta of 1.23. The company’s 50-day simple moving average is $36.65 and its two-hundred day simple moving average is $31.46. Roivant Sciences has a one year low of $19.30 and a one year high of $42.50.
Insider Buying and Selling
In other Roivant Sciences news, Director Melissa B. Epperly sold 17,750 shares of Roivant Sciences stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $36.10, for a total value of $640,775.00. Following the transaction, the director directly owned 14,954 shares of the company’s stock, valued at approximately $539,839.40. The trade was a 54.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction on Tuesday, October 20th. The stock was sold at an average price of $35.11, for a total value of $7,022,000.00. Following the transaction, the chief executive officer directly owned 1,399,154 shares in the company, valued at approximately $49,124,296.94. The trade was a 12.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,822,688 shares of company stock worth $66,176,636 in the last 90 days. 8.80% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on ROIV. Jefferies Financial Group lifted their price objective on shares of Roivant Sciences from $42.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, October 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 24th. Finally, Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $46.55.
Get Our Latest Analysis on ROIV
About Roivant Sciences
Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.
Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.
Featured Stories
- Five stocks we like better than Roivant Sciences
- Royal Caribbean Buys the Beach as Norwegian Fixes the Ship
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
